0M2N Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €57.20 |
| 52 Week High | €56.90 |
| 52 Week Low | €37.10 |
| Beta | 0.34 |
| 1 Month Change | 15.90% |
| 3 Month Change | 10.21% |
| 1 Year Change | n/a |
| 3 Year Change | 51.59% |
| 5 Year Change | 29.56% |
| Change since IPO | 235.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M2N | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.1% | 0.7% | 1.1% |
| 1Y | n/a | -12.3% | 0.8% |
Return vs Industry: Insufficient data to determine how 0M2N performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0M2N performed against the UK Market.
Price Volatility
| 0M2N volatility | |
|---|---|
| 0M2N Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0M2N has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0M2N's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,943 | Liisa Hurme | www.orionpharma.com |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| 0M2N fundamental statistics | |
|---|---|
| Market cap | €8.04b |
| Earnings (TTM) | €347.40m |
| Revenue (TTM) | €1.59b |
Is 0M2N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M2N income statement (TTM) | |
|---|---|
| Revenue | €1.59b |
| Cost of Revenue | €610.90m |
| Gross Profit | €977.60m |
| Other Expenses | €630.20m |
| Earnings | €347.40m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
| Earnings per share (EPS) | 2.47 |
| Gross Margin | 61.54% |
| Net Profit Margin | 21.87% |
| Debt/Equity Ratio | 30.1% |
How did 0M2N perform over the long term?
See historical performance and comparisonDividends
Does 0M2N pay a reliable dividends?
See 0M2N dividend history and benchmarks| Orion Oyj dividend dates | |
|---|---|
| Ex Dividend Date | Oct 15 2025 |
| Dividend Pay Date | Oct 23 2025 |
| Days until Ex dividend | 147 days |
| Days until Dividend pay date | 155 days |
Does 0M2N pay a reliable dividends?
See 0M2N dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 20:33 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orion Oyj is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Graham Glyn Parry | BofA Global Research |
| Charlie Haywood | BofA Global Research |